# Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

> **NCT01317004** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 61 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod
- **DRUG:** Standard MS DMT

## Key facts

- **NCT ID:** NCT01317004
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2015-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01317004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01317004, "Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01317004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*